Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] Group 1 - The approved product, Entacapone tablets, is indicated for use alongside standard medications such as Levodopa/Benserazide or Levodopa/Carbidopa [1] - The primary application of Entacapone is to treat Parkinson's disease and address symptoms that are not controlled by existing therapies [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] Group 1 - The approved product, Entacapone, is indicated for use alongside standard medications such as Levodopa/benserazide or Levodopa/carbidopa [1] - Entacapone is specifically aimed at treating Parkinson's disease and addressing motor fluctuations that cannot be controlled by existing therapies [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Entacapone tablets, which are prescription drugs that assist in the treatment of Parkinson's disease and end-of-dose wearing-off phenomena, classified as a Category B item in the medical insurance directory [1] Group 1 - The approved drug is expected to generate approximately 286 million yuan in sales for public medical institutions in China in 2024 [1] - This approval enhances the company's formulation product portfolio and improves its overall competitiveness [1] - The sales of the drug may be influenced by policies and market factors, leading to uncertainties [1]

Group 1 - The core point of the article is that Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, indicating a significant development for the company [1] Group 2 - Xinhua Pharmaceutical's stock closed at 15.15 yuan on March 4 [1] - The product name approved is "Entacapone tablets," which suggests potential new revenue streams for the company [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of Entacapone tablets, which will enhance the company's product portfolio and competitive strength in the pharmaceutical market [1] Group 1: Product Approval - The company has obtained the drug registration certificate for Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] - Entacapone tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] Group 2: Market Potential - The estimated sales revenue for Entacapone tablets in Chinese public medical institutions is approximately RMB 286 million in 2024 [1] - The approval of Entacapone tablets will further enrich the company's formulation product series, contributing to an increase in overall competitiveness [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] Company Summary - The approved product, Entacapone tablets, is indicated for use alongside standard medications such as Levodopa/Benserazide or Levodopa/Carbidopa [1] - The indication for Entacapone includes treatment for Parkinson's disease and symptom fluctuations that are not controlled by existing therapies [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Entacapone tablets, which will enhance the company's product portfolio and competitive strength in the pharmaceutical market [1] Group 1: Product Approval - The company has obtained the drug registration certificate for Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] - Entacapone tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) [1] Group 2: Market Potential - The estimated sales revenue for Entacapone tablets in Chinese public medical institutions is approximately RMB 286 million in 2024 [1] - The approval of Entacapone tablets will further enrich the company's formulation product series, contributing to an increase in overall competitiveness [1]